Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amy W. Peng"'
Publikováno v:
The Journal of Clinical Pharmacology. 40:242-249
The pharmacokinetics of zanamivir were evaluated in subjects from three phase I single-center and two phase II multicenter, randomized, double-blind, multidose, placebo-controlled trials. A total of 96 phase I subjects received zanamivir (3.6 to 16 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b3530a42fdb583e4ece2659d6d22c0
https://doi.org/10.1177/00912700022008900
https://doi.org/10.1177/00912700022008900
Publikováno v:
Current Therapeutic Research. 61:36-46
Objective The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of zanamivir in children. Background Zanamivir is a potent inhibitor of viral neuraminidase that is effective against both influenza A and B infections.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d0a4a93c143bffb75f4ef622b1dc744
https://doi.org/10.1016/s0011-393x(00)88495-7
https://doi.org/10.1016/s0011-393x(00)88495-7
Autor:
Amy W. Peng, David P. Calfee, Warren Strober, W. Gregory Alvord, Lindsey Cass, Sharon E. Straus, Frederick G. Hayden, R. Scott Fritz
Publikováno v:
The Journal of Infectious Diseases. 180:586-593
The local immune response to influenza virus infection was characterized by determining cytokine and chemokine levels in serial nasal lavage fluid samples from 15 volunteers experimentally infected with influenza A/Texas/36/91 (H1N1). The study was p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd54980cf3e6b4ec9ea577aac65092bb
https://doi.org/10.1086/314938
https://doi.org/10.1086/314938
Publikováno v:
Antiviral Therapy. 4:143-149
Zanamivir, a potent inhibitor of influenza A and B virus neuraminidases, is protective against experimental human influenza when given intranasally twice daily. We conducted two studies to assess the pharmacokinetics and protective efficacy of a redu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a722506cacc7cf013205a1a6f419614f
https://doi.org/10.1177/135965359900400302
https://doi.org/10.1177/135965359900400302
Autor:
H. Mitchell Perry, Mark A. Sirgo, Amy W. Peng, Deborah L. Due, Raymond R. Townsend, David W. Bartels, Joan Ryder Benz, John B. Kostis, W. Dallas Hall
Publikováno v:
The American Journal of Medicine. 96:77-86
purpose: This trial was designed to evaluate the efficacy and safety of three different classes of antihypertensive agents in elderly women. patients and methods: The trial had three phases: 4 to 8 weeks of placebo, 6 weeks of titration, and 16 weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd104abf1940efa935afcf9b02afd12
https://doi.org/10.1016/0002-9343(94)90118-x
https://doi.org/10.1016/0002-9343(94)90118-x
Publikováno v:
Antimicrobial Agents and Chemotherapy. 44:1974-1976
In a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::730647968921b09baba9000264a40520
https://doi.org/10.1128/aac.44.7.1974-1976.2000
https://doi.org/10.1128/aac.44.7.1974-1976.2000
Zanamivir is a potent inhibitor of influenza A and B virus neuraminidases and is active topically in experimental and natural human influenza. We conducted this double-blinded, placebo-controlled study to evaluate the safety and efficacy of intraveno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974b9fad542a119dc29ca31cd78a89c8
https://europepmc.org/articles/PMC89333/
https://europepmc.org/articles/PMC89333/
